(0.37%) 5 199.84 points
(0.23%) 38 942 points
(0.29%) 16 396 points
(0.51%) $78.88
(-0.14%) $2.19
(-0.38%) $2 322.30
(-0.20%) $27.56
(2.47%) $988.75
(0.10%) $0.929
(0.67%) $10.90
(0.34%) $0.799
(-0.11%) $91.24
Live Chart Being Loaded With Signals
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally...
Stats | |
---|---|
आज की मात्रा | 1.79M |
औसत मात्रा | 1.68M |
बाजार मूल्य | 0.00 |
EPS | £0.0264 ( 2020-09-29 ) |
Last Dividend | £5.46 ( 2021-12-02 ) |
Next Dividend | £0 ( N/A ) |
P/E | 0.410 |
ATR14 | £0 (0.00%) |
Clinigen Group PLC सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
ARE.L | 0.952 |
3USS.L | 0.942 |
3ULS.L | 0.939 |
XPD.L | 0.936 |
MNZS.L | 0.93 |
PBLT.L | 0.925 |
GAW.L | 0.91 |
GPH.L | 0.891 |
IGE.L | 0.878 |
AIBG.L | 0.876 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
YGEN.L | -0.965 |
DNM.L | -0.942 |
ECHO.L | -0.941 |
FRG.L | -0.932 |
EXR.L | -0.932 |
3NGL.L | -0.931 |
SIXH.L | -0.925 |
GIF.L | -0.921 |
VCAP.L | -0.911 |
MAST.L | -0.911 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Clinigen Group PLC वित्तीय
Annual | 2021 |
राजस्व: | £523.60M |
सकल लाभ: | £197.90M (37.80 %) |
EPS: | £0.233 |
FY | 2021 |
राजस्व: | £523.60M |
सकल लाभ: | £197.90M (37.80 %) |
EPS: | £0.233 |
FY | 2020 |
राजस्व: | £504.30M |
सकल लाभ: | £220.00M (43.62 %) |
EPS: | £0.103 |
FY | 2019 |
राजस्व: | £456.90M |
सकल लाभ: | £182.30M (39.90 %) |
EPS: | £0.0400 |
Financial Reports:
No articles found.
Clinigen Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £0.600 | 2013-03-06 |
Last Dividend | £5.46 | 2021-12-02 |
Next Dividend | £0 | N/A |
Payout Date | 2022-01-04 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | £45.62 | -- |
Avg. Dividend % Per Year | 0.20% | -- |
Score | 3.37 | -- |
Div. Sustainability Score | 9.57 | |
Div.Growth Potential Score | 4.52 | |
Div. Directional Score | 7.04 | -- |
Year | Amount | Yield |
---|---|---|
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £5.60 | 0.64% |
2019 | £6.70 | 0.91% |
2020 | £7.61 | 0.83% |
2021 | £7.61 | 1.09% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WTAN.L | Dividend King | 2023-08-24 | Quarterly | 53 | 1.48% | |
NEXS.L | Dividend Junior | 2023-06-01 | Annually | 8 | 0.56% | |
EGY.L | Dividend King | 2023-08-24 | Quarterly | 3 | 2.58% | |
SPO.L | Dividend Knight | 2023-07-27 | Sporadic | 3 | 61.25% | |
JAGI.L | Dividend King | 2023-07-13 | Quarterly | 27 | 2.39% | |
BSC.L | Dividend Knight | 2023-10-05 | Semi-Annually | 20 | 5.24% | |
PHP.L | Dividend King | 2023-07-06 | Quarterly | 28 | 2.84% | |
FOUR.L | Dividend Knight | 2023-08-17 | Annually | 32 | 1.87% | |
AAS.L | Dividend Knight | 2023-08-24 | Semi-Annually | 29 | 1.07% | |
TGA.L | Dividend Royal | 2023-09-20 | Semi-Annually | 3 | 21.05% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0579 | 1.500 | 8.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0284 | 1.200 | 9.05 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0679 | 1.500 | -0.357 | -0.535 | [0.1 - 1] |
payoutRatioTTM | 0.333 | -1.000 | 6.67 | -6.67 | [0 - 1] |
currentRatioTTM | 1.752 | 0.800 | 6.24 | 4.99 | [1 - 3] |
quickRatioTTM | 0.480 | 0.800 | -1.884 | -1.507 | [0.8 - 2.5] |
cashRatioTTM | 0.480 | 1.500 | 8.45 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.393 | -1.500 | 3.45 | -5.18 | [0 - 0.6] |
interestCoverageTTM | 5.00 | 1.000 | 9.26 | 9.26 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.348 | 2.00 | 9.88 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.130 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.937 | -1.500 | 6.25 | -9.38 | [0 - 2.5] |
grossProfitMarginTTM | 0.378 | 1.000 | 7.03 | 7.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.112 | 1.000 | 9.77 | 9.77 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.108 | 1.000 | -0.511 | -0.511 | [0.2 - 2] |
assetTurnoverTTM | 0.491 | 0.800 | -0.0576 | -0.0460 | [0.5 - 2] |
Total Score | 9.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.63 | 1.000 | 6.10 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0679 | 2.50 | -0.229 | -0.535 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.130 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.348 | 2.00 | 9.88 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.333 | 1.500 | 6.67 | -6.67 | [0 - 1] |
pegRatioTTM | 25.76 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0863 | 1.000 | -0.342 | 0 | [0.1 - 0.5] |
Total Score | 4.52 |
Clinigen Group PLC
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं